Commentary

Video

Frontline Treatment Considerations in Adult and Pediatric Acute Lymphoblastic Leukemia

Author(s):

George Yaghmour, MD,Rachel Elizabeth Rau, MD

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on factors for frontline treatment in adult and pediatric acute lymphoblastic leukemia.

Related Videos
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Ashkan Emadi, MD, PhD
Peter Riedell, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Related Content
Nirav N. Shah, MD
January 7th 2025

Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
Published: January 6th 2025 | Updated: January 8th 2025

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia

Mark Agulnik, MD, professor, clinical medicine, vice chair, faculty development, Department of Medicine, section chief, Sarcomas & Melanoma, Keck School of Medicine, the University of Southern California
June 24th 2024

Agulnik Highlights Key Updates in GIST Research and Management

Margaret A. Shipp, MD, of Dana-Farber
December 31st 2024

Shipp’s Passion Leads to Transformative Research, Innovations in Lymphoma

OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology